Pliant Therapeutics announced that the latest data from the Phase 1 clinical trial of its investigational drug Pln-101095 for patients with immune checkpoint inhibitor (ICI)-refractory solid tumors will be presented in a special report at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin Edges Higher as Treasury Yields, Dollar Ease -- Market Talk
Morgan Stanley is tactically bullish on BHP (BHP.US): Two major copper mine catalysts may ignite the stock price in the next two months
Morgan Stanley maintains an "Overweight" rating on BHP Group, with an "attractive" industry outlook, and sets a target price of AUD 69.00 for its shares listed in Australia.
Bank of England hawkish official: Growth exceeds expectations and employment is resilient, which precisely proves that further rate hikes are necessary.
Megan Greene, a policymaker at the Bank of England, stated that the UK's economic growth surpassing expectations and the resilience of the job market indicate that the Bank of England's efforts to curb inflation are still insufficient.
Crypto prices
More
